Pain in fingers; Psoriasis flare-up; COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19), PSORIASIS (Psoriasis flare-up) and PAIN IN EXTREMITY (Pain in fingers) in a 54-year-old female patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriatic arthritis.    Concurrent medical conditions included Psoriasis and Psoriatic arthritis.   On 04-Nov-2021, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient received first dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Spikevax) (Intramuscular) dosage was changed to 1 dosage form and third dose of mRNA-1273 (Spikevax) (Intramuscular) dosage was changed to 1 dosage form. On 15-Jan-2022, the patient experienced COVID-19 (COVID-19). In March 2022, the patient experienced PSORIASIS (Psoriasis flare-up). On an unknown date, the patient experienced PAIN IN EXTREMITY (Pain in fingers). At the time of the report, COVID-19 (COVID-19) and PSORIASIS (Psoriasis flare-up) had resolved and PAIN IN EXTREMITY (Pain in fingers) outcome was unknown.            The patient experienced achiness in figure/ sharp pain in them from time to time when reaches out to grab things.  No concomitant medication were reported.   No treatment drug were reported.  Company Comment: This spontaneous case concerns a 54-year-old, female patient with pre-existing psoriasis and psoriatic arthritis with ongoing Adalimumab (Humira) treatment, who experienced the unexpected, non-serious adverse event of special interest COVID-19. Non-serious events of Psoriasis, described as ocassional flare-up with Humira, and Pain in extremity specifically the fingers were also reported. The events, with COVID-19 occurring 2 months prior to the reported psoriasis, were experienced after receiving three doses of mRNA-1273, administered on unknown dates. Presenting symptoms, clinical course and medical intervention administered were not provided in the case. The ongoing COVID-19 pandemic remains a confounder for the event of COVID-19; while the pre-existing autoimmune disease, given the nature of psoriasis to be a chronic disease with periods of remission and relapse, remains a confounder for the flare-up. Additionally, the psoriatic arthritis could be a contributor to the pain in extremity. The co-suspect Adalimumab, being an immunosuppressant, could have contributed in increasing the patient's risk to contracting the COVID-19 infection. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a 54-year-old, female patient with pre-existing psoriasis and psoriatic arthritis with ongoing Adalimumab (Humira) treatment, who experienced the unexpected, non-serious adverse event of special interest COVID-19. Non-serious events of Psoriasis, described as ocassional flare-up with Humira, and Pain in extremity specifically the fingers were also reported. The events, with COVID-19 occurring 2 months prior to the reported psoriasis, were experienced after receiving three doses of mRNA-1273, administered on unknown dates. Presenting symptoms, clinical course and medical intervention administered were not provided in the case. The ongoing COVID-19 pandemic remains a confounder for the event of COVID-19; while the pre-existing autoimmune disease, given the nature of psoriasis to be a chronic disease with periods of remission and relapse, remains a confounder for the flare-up. Additionally, the psoriatic arthritis could be a contributor to the pain in extremity. The co-suspect Adalimumab, being an immunosuppressant, could have contributed in increasing the patient's risk to contracting the COVID-19 infection. The benefit-risk relationship of mRNA-1273 is not affected by this report.